Clinical trials: Leiomyosarcoma Metastatic
Sarcoma
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00033709
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Cancer, Tumor, Solid
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805…
- Conditions
- Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
- Trial name
- NCT05094804
- Testing
- OR2805, Cemiplimab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoResponse, Inc.
Leiomyosarcoma
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
Dinutuximab beta was designed to bind to neuroblastoma cells and other cancer cells that express the GD2 antigen, such as STS/LMS cells, and it is believed that this binding "labels" the cells an makes them a better target.
- Trial name
- DiTuSarc (NCT05080790)
- Testing
- Dinutuximab Beta, Zoledronic acid, Interleukin-2
- Where
- 2 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Leiomyosarcoma
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have…
- Trial name
- NCT03437070
- Testing
- Trabectedin, Doxorubicin, Olaratumab
- Sponsor
- University of Miami
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma
RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving…
- Trial name
- NCT00334984
- Testing
- glutamine, chemoprotection, management of therapy complications
- Sponsor
- Children's Oncology Group
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00112463
- Testing
- romidepsin
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide or doxorubicin is more effective for advanced or metastatic soft…
- Trial name
- NCT00003212
- Testing
- doxorubicin hydrochloride, ifosfamide
- Where
- 23 sites in Belgium, Denmark and 8 more
- Volunteers
- 780 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leiomyosarcoma
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
The primary objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of unesbulin in combination with dacarbazine for the treatment of advanced LMS and determine the overall…
- Trial name
- NCT03761095
- Testing
- Unesbulin, Dacarbazine
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- PTC Therapeutics
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Leiomyosarcoma
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
The aim of this research is to study the activity of pazopanib in second line after anthracyclines in extra uterus and uterine LMS in association with gemcitabine.
- Trial name
- LMS03 (NCT01442662)
- Testing
- pazopanib + gemcitabine
- Where
- 17 sites in France
- Volunteers
- 106 people
- Sponsor
- UNICANCER
Uterine or Soft Tissue Leiomyosarcoma
Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma
The objective of LMS04 study is to better define the treatment strategy for patients with metastatic leiomyosarcoma (uterine or soft tissue), as well as identifying the best first line therapeutic option for these patients.
- Trial name
- LMS04 (NCT02997358)
- Testing
- Doxorubicin, Trabectedin
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Liposarcoma, Leiomyosarcoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
- Trial name
- NCT00060944
- Testing
- Yondelis, Dexamethasone
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
- Trial name
- NCT00069940
- Testing
- sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Kidney Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Kidney Cancer, Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00002764
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- Sweden
- Volunteers
- 340 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer, Sarcoma
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as brostallicin and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00410462
- Testing
- brostallicin, doxorubicin hydrochloride
- Where
- Netherlands
- Volunteers
- 118 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Trial name
- NCT03074318
- Testing
- Avelumab, Trabectedin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma, Soft Tissue, Soft Tissue Sarcoma
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this research study is to look at whether giving a drug called dexrazoxane with standard of care doxorubicin affects the progression of the disease.
- Conditions
- Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
- Trial name
- NCT02584309
- Testing
- Dexrazoxane, Doxorubicin
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Washington University School of Medicine
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT04200443
- Testing
- Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- City of Hope Medical Center
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Lurbinectedin + Doxorubicin In Leiomyosarcoma
This research study involves the study drug lurbinectedin in combination with doxorubicin. This research has two parts. The first part is being done to determine the tolerability of lurbinectedin with doxorubicin in people with…
- Conditions
- Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
- Trial name
- NCT05099666
- Testing
- Lurbinectedin, Doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital